HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Oral adjuvant clodronate therapy could improve overall survival in early breast cancer: results from an updated systematic review and meta-analysis.

AbstractOBJECT:
The aim of this study was to evaluate the effectiveness of clodronate in the adjuvant therapy of early breast cancer on patient survival.
METHODS:
We performed a literature search to identify studies that investigated the effects of clodronate treatment on early breast cancer. Random and fixed-effect meta-analytical models were used where indicated and between-study heterogeneity was assessed. The primary study end-points were overall survival. Secondary end-points were bone metastasis-free survival and non-skeletal metastasis (mainly visceral metastases) free survival.
RESULTS:
Four randomised controlled trials met the inclusion criteria. Risk ratio (95% confidence interval (CI)) of overall survival was 0.84 (0.56-1.26); risk ratio (95% CI) of bone metastasis-free survival was 0.77 (0.58-1.02); risk ratio (95% CI) of non-bone metastasis-free survival was 0.89 (0.61-1.30). Outcomes after sensitivity analysis were: risk ratio (95% CI) of overall survival was 0.71 (0.52-0.96); risk ratio (95% CI) of bone metastasis-free survival was 0.70 (0.56-0.86); risk ratio (95% CI) of non-bone metastasis-free survival was 0.76 (0.64-0.92).
CONCLUSION:
Compared with the control arm, adjuvant treatment with clodronate may improve the overall survival, bone metastasis-free survival and non-bone metastasis-free (mainly visceral metastases) survival in patients with early breast cancer. However, further meta-analyses involving all known randomised trials with analysis of sub-groups by age or menopausal status, accessing original trial data, should be performed.
AuthorsJianhong Zhu, Yayuan Zheng, Zhikun Zhou
JournalEuropean journal of cancer (Oxford, England : 1990) (Eur J Cancer) Vol. 49 Issue 9 Pg. 2086-92 (Jun 2013) ISSN: 1879-0852 [Electronic] England
PMID23452992 (Publication Type: Journal Article, Meta-Analysis, Review, Systematic Review)
CopyrightCopyright © 2013 Elsevier Ltd. All rights reserved.
Chemical References
  • Antineoplastic Agents
  • Bone Density Conservation Agents
  • Clodronic Acid
Topics
  • Administration, Oral
  • Adult
  • Aged
  • Antineoplastic Agents (administration & dosage)
  • Bone Density Conservation Agents (administration & dosage)
  • Bone Neoplasms (drug therapy, mortality, secondary)
  • Breast Neoplasms (drug therapy, mortality)
  • Clodronic Acid (administration & dosage)
  • Disease-Free Survival
  • Female
  • Humans
  • Middle Aged
  • Prospective Studies
  • Randomized Controlled Trials as Topic

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: